In the Netherlands, people with central disorders of hypersomnolence used cannabis at nearly twice the rate of the general population, with 57% of current users saying symptom improvement motivated their use and 79% reporting cannabis affected their symptoms — mostly positively.
Sleep medicine specialists, narcolepsy patients, and researchers studying the endocannabinoid system's role in sleep-wake regulation.
What the researchers found
Lifetime cannabis use (42% vs 23%, p significant) and current use were both significantly higher among people with central disorders of hypersomnolence (CDH) compared to the Dutch general population. Among current users, 57% used cannabis to improve CDH symptoms, and 79% reported symptom effects — mostly positive (43%), some mixed (29%), and few negative (7%).
Why it matters
Central disorders of hypersomnolence (including narcolepsy) have limited treatment options. The fact that patients are already self-medicating with cannabis at high rates — and reporting mostly positive effects — provides a rationale for formal clinical investigation of cannabinoids for these conditions.
The numbers in context
76 of 88 patients responded. Lifetime cannabis use: 42% vs 23% general population. 57% of current users motivated by symptom improvement. 79% reported cannabis effects on symptoms: 43% positive, 29% mixed, 7% negative. Former users mostly started before symptom onset for recreational purposes.
How the study worked
Online questionnaire completed by 76 of 88 patients with central disorders of hypersomnolence in the Netherlands. Cannabis use patterns were compared to Dutch general population rates. Symptom motivations and perceived effects were assessed among current and former users.
What this study cannot tell us
Small sample (n=76), single country (Netherlands where cannabis is accessible). Self-reported effects with no objective sleep measures. No control for placebo effect. CDH encompasses multiple conditions that may respond differently.
How to read the evidence
Cross-sectional survey with reasonable response rate, but small sample and self-reported outcomes without objective verification.
When this study was published
Published 2025.
The bigger picture
The endocannabinoid system is known to play a role in sleep-wake regulation. This study provides real-world evidence that CDH patients are already using cannabis therapeutically and perceiving benefit, strengthening the case for clinical trials of cannabinoids in hypersomnolence.
Questions still open
- Which specific cannabinoids (THC, CBD, or both) are most effective for hypersomnolence symptoms? Would objective sleep studies confirm the subjective improvements? Could cannabis interact with standard narcolepsy medications?
Common questions
Can cannabis help with excessive sleepiness?
Why might the endocannabinoid system affect sleepiness?
Read the original research
Cannabis Use in Central Disorders of Hypersomnolence in the Netherlands.
Medical cannabis and cannabinoids, 8(1), 181-187
Citation
Vringer, Marieke; Cronie, Michel; Remmerswaal, Aniek; Klumpers, Linda E; Lammers, Gert Jan; Fronczek, Rolf; Schinkelshoek, Mink S. (2025). Cannabis Use in Central Disorders of Hypersomnolence in the Netherlands.. Medical cannabis and cannabinoids, 8(1), 181-187. https://doi.org/10.1159/000548416
Explore the wider topic
- Cannabis and Sleep: Does It Actually Help or Just Mask the Problem?
- How to Sleep Without Weed: 12 Methods That Actually Work
- Can You Take Melatonin During Weed Withdrawal?
- Nightmares After Quitting Weed: Why They Happen and When They Stop
- The Complete Sleep Recovery Timeline After Quitting Weed
- THC and REM Sleep Rebound: Why Your Dreams Go Wild When You Quit
- Weed Withdrawal Dreams: Why Your Dreams Are So Vivid and Intense
- Weed Withdrawal Insomnia: Why You Can't Sleep and What Actually Helps